Sotrovimab Clinical, Safety, & Variant Information

5/26 Early treatment study

GlaxoSmithKline (Preprint)
Sotrovimab Clinical, Safety, & Variant Information

Interim results from the COMET-ICE trial showing lower mortality and progression with treatment. NCT04545060.

GlaxoSmithKline et al., 5/26/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 1 author.

risk of death, 66.6% lower, RR 0.33, p = 1.00, treatment 0 of 291 (0.0%), control 1 of 292 (0.3%), continuity correction due to zero event (with reciprocal of the contrasting arm).

risk of disease progression, 85.0% lower, RR 0.15, p = 0.002, treatment 3 of 291 (1.0%), control 21 of 292 (7.2%), adjusted per study.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 1 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit